Mabpharm-B Reports Annual Profit Turnaround with CNY57.1 Million Net Income
Stock News
Mar 26
Mabpharm-B (02181) announced its financial results for the year ended December 31, 2025. The company recorded revenue of CNY646 million, representing a year-on-year increase of 150.2%. Profit attributable to owners of the company was CNY57.1 million, a significant improvement from a loss in the previous year. Basic earnings per share were CNY0.01. The turnaround to profitability was primarily attributed to an increase in gross profit and the recognition of deductible income tax for the coming year as a deferred tax expense.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.